Literature DB >> 10654860

Evidence of declining STD prevalence in a South African mining community following a core-group intervention.

R Steen1, B Vuylsteke, T DeCoito, S Ralepeli, G Fehler, J Conley, L Bruckers, G Dallabetta, R Ballard.   

Abstract

OBJECTIVES: To reduce the prevalence of curable sexually transmitted diseases (STDs) in a South African mining community through provision of STD treatment services, including periodic presumptive treatment and prevention education to a core group of high-risk women living in areas around the mines.
METHODS: Women at high risk for STDs attended a mobile clinic monthly for examination and counseling, and were treated presumptively for bacterial STDs with a directly observed 1-g dose of azithromycin. Gonococcal and chlamydial infection rates were measured by urine ligase chain reaction, and genital ulcers were assessed by clinical examination. Changes in STD prevalence among local miners were assessed through comparison of prevalence in two cross-sectional samples of miners taken 9 months apart, and through routine disease surveillance at mine health facilities.
RESULTS: During the first 9 months of the intervention, 407 women used the services. Baseline prevalence of Neisseria gonorrhoeae and/or Chlamydia trachomatis in women was 24.9%; 9.7% of these women had clinical evidence of genital ulcer disease (GUD). The proportion of women with incident gonococcal or chlamydial infections at the first monthly return visit (69% follow-up rate) was 12.3%, and genital ulcers were found in 4.4% of these women. In the miner population, the prevalence of N gonorrhoeae and/or C trachomatis was 10.9% at baseline and 6.2% at the 9-month follow-up examination (P<0.001). The prevalence of GUD by clinical examination was 5.8% at baseline and 1.3% at follow-up examination (P< 0.001). Rates of symptomatic STDs seen at mine health facilities decreased among miners in the intervention area compared with miners living farther from the site and with less exposure to the project. DISCUSSION: Provision of STD treatment services to a core group of high-risk women may significantly reduce their burden of disease, and may contribute to a reduction in community STD prevalence. In the absence of sensitive and affordable screening tests for STDs in women, periodic presumptive treatment coupled with prevention education is a feasible approach to providing STD services in this population.

Entities:  

Keywords:  Africa; Africa South Of The Sahara; Delivery Of Health Care; Developing Countries; Diseases; Economic Factors; English Speaking Africa; Health; Health Services; Human Resources; Infections; Labor Force; Longitudinal Studies; Migrant Workers; Population At Risk; Reproductive Tract Infections; Research Methodology; Research Report; Sexually Transmitted Diseases--prevention and control; South Africa; Southern Africa; Studies; Treatment

Mesh:

Substances:

Year:  2000        PMID: 10654860     DOI: 10.1097/00007435-200001000-00001

Source DB:  PubMed          Journal:  Sex Transm Dis        ISSN: 0148-5717            Impact factor:   2.830


  32 in total

Review 1.  Sexual risk behaviour and infection: epidemiological considerations.

Authors:  S O Aral
Journal:  Sex Transm Infect       Date:  2004-12       Impact factor: 3.519

2.  Killing of dsrA mutants of Haemophilus ducreyi by normal human serum occurs via the classical complement pathway and is initiated by immunoglobulin M binding.

Authors:  Malikah Abdullah; Igor Nepluev; Galyna Afonina; Sanjay Ram; Peter Rice; William Cade; Christopher Elkins
Journal:  Infect Immun       Date:  2005-06       Impact factor: 3.441

3.  The Bali STD/AIDS study: association between vaginal hygiene practices and STDs among sex workers.

Authors:  B D Reed; K Ford; D N Wirawan
Journal:  Sex Transm Infect       Date:  2001-02       Impact factor: 3.519

4.  STI declines among sex workers and clients following outreach, one time presumptive treatment, and regular screening of sex workers in the Philippines.

Authors:  T Wi; E R Ramos; R Steen; T A Esguerra; M C R Roces; M C Lim-Quizon; G Neilsen; G Dallabetta
Journal:  Sex Transm Infect       Date:  2006-10       Impact factor: 3.519

Review 5.  Sentinel surveillance of sexually transmitted infections in South Africa: a review.

Authors:  L F Johnson; D J Coetzee; R E Dorrington
Journal:  Sex Transm Infect       Date:  2005-08       Impact factor: 3.519

6.  Sexually transmitted infection (STI) testing among young oil and gas workers: the need for innovative, place-based approaches to STI control.

Authors:  Shira M Goldenberg; Jean A Shoveller; Aleck C Ostry; Mieke Koehoorn
Journal:  Can J Public Health       Date:  2008 Jul-Aug

7.  Review of STI and HIV epidemiological data from 1990 to 2001 in urban Burkina Faso: implications for STI and HIV control.

Authors:  N Nagot; N Meda; A Ouangre; A Ouedraogo; S Yaro; I Sombie; M C Defer; H Barennes; P Van de Perre
Journal:  Sex Transm Infect       Date:  2004-04       Impact factor: 3.519

8.  Baseline survey of sexually transmitted infections in a cohort of female bar workers in Mbeya Region, Tanzania.

Authors:  G Riedner; M Rusizoka; O Hoffmann; F Nichombe; E Lyamuya; D Mmbando; L Maboko; P Hay; J Todd; R Hayes; M Hoelscher; H Grosskurth
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

9.  Sexually transmitted infections in male clients of female sex workers in Benin: risk factors and reassessment of the leucocyte esterase dipstick for screening of urethral infections.

Authors:  M Alary; C M Lowndes; L Mukenge-Tshibaka; C A B Gnintoungbé; E Bédard; N Geraldo; P Jossou; E Lafia; F Bernier; E Baganizi; J R Joly; E Frost; S Anagonou
Journal:  Sex Transm Infect       Date:  2003-10       Impact factor: 3.519

10.  Prevalence of sexually transmitted infections and performance of STI syndromes against aetiological diagnosis, in female sex workers of red light area in Surat, India.

Authors:  V K Desai; J K Kosambiya; H G Thakor; D D Umrigar; B R Khandwala; K K Bhuyan
Journal:  Sex Transm Infect       Date:  2003-04       Impact factor: 3.519

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.